Bronnen:
Drilon A, et al. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children. N Engl J Med. 2018;378:731-739.,European Medicines Agency. Summary of opinion (initial authorisation). Vitrakvi larotrectinib. 25 July 2019. Beschikbaar via: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vitrakvi_en.pdf,Marchiò C, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 2019;0:1–11. doi:10.1093/annonc/mdz204.,ESMO 2019 Industry Satellite Symposium (Bayer) ‘Optimizing treatment in the era of precision oncology- a multidisciplinary approach.’ Zondag 29 september 2019. Barcelona, Spanje.
Drilon A, et al. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children. N Engl J Med. 2018;378:731-739.,European Medicines Agency. Summary of opinion (initial authorisation). Vitrakvi larotrectinib. 25 July 2019. Beschikbaar via: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vitrakvi_en.pdf,Marchiò C, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 2019;0:1–11. doi:10.1093/annonc/mdz204.,ESMO 2019 Industry Satellite Symposium (Bayer) ‘Optimizing treatment in the era of precision oncology- a multidisciplinary approach.’ Zondag 29 september 2019. Barcelona, Spanje.